Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Peter Clark, MA, MD, FRCP: A Payer Perspective

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement




Jun
29
Today In Oncology
I Miss My Life
AACR Cancer Disparities Progress Report Mortality Rates Improve But Care Inequities Persist
Fertility Preservation Access Remains Limited and Unequal for Many Girls and Young Women With Cancer
Adverse Events With CD3-Based T-Cell–Engaging Bispecific Antibody Treatment in Cancer
Survey Results Show Patients Prefer Learning of a Diagnosis From Their Doctor Rather Than a Health Portal
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo